RxDoctor Payments Data

Stephanie Hayes

Surgical · Boise, IDNPI 1427503721

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 42.0% of the total. 2025 is the largest year on record at $146, 9.6 times the $15 reported in 2021. That places this record below the midpoint for surgical clinicians in ID, where the typical reported total is $329.

$293in general payments, 2019–2025

Across 9 payments — averaging $32.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$123
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42
  • Edwards Lifesciences$32
  • Pfizer$23
  • AstraZeneca$21
  • Boston Scientific$19
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$293 in reported general payments places this provider in the 45th percentile of 78 surgical providers in Idaho.

See all surgical providers in Idaho

Medicare billing

Part B allowed, 2024
$33,144
Medicare patients
296
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$235,490
EntrestoSacubitril/Valsartan30$46,183
JardianceEmpagliflozin27$44,680
FarxigaDapagliflozin Propanediol40$38,976
XareltoRivaroxaban25$34,049
Metoprolol Succinate353$5,002
Rosuvastatin Calcium193$2,847
Atorvastatin Calcium252$2,316
Potassium Chloride151$2,289
Amiodarone Hcl12$1,654
Ezetimibe74$1,470
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,399
Torsemide64$1,143
Carvedilol116$1,045
Losartan Potassium145$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$235,490197 claims
AstraZenecaFarxiga$21$38,97640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 78 surgical providers in Idaho.

Other surgical in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →